1. Home
  2. BLNK vs KRRO Comparison

BLNK vs KRRO Comparison

Compare BLNK & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.58

Market Cap

94.6M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$11.28

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
KRRO
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.6M
109.7M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
BLNK
KRRO
Price
$0.58
$11.28
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$1.95
$34.80
AVG Volume (30 Days)
1.5M
204.9K
Earning Date
05-11-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
38.94
N/A
EPS
N/A
N/A
Revenue
$126,197,000.00
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$0.54
$5.20
52 Week High
$2.65
$55.89

Technical Indicators

Market Signals
Indicator
BLNK
KRRO
Relative Strength Index (RSI) 36.72 48.33
Support Level N/A $10.55
Resistance Level $0.72 $14.96
Average True Range (ATR) 0.03 0.87
MACD -0.01 -0.11
Stochastic Oscillator 28.00 19.72

Price Performance

Historical Comparison
BLNK
KRRO

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: